somatotropin release inhibitory factor; renal; mesangium; immunohistochemistry; reverse transcriptase-polymerase chain reaction SOMATOSTATIN IS WELL RECOGNIZED for its role as a neuropeptide, a hypothalamic inhibitor of growth hormone release, and a paracrine inhibitor of gut peptide secretion (21) . Somatostatin also serves to modulate renal cell function and growth. Intravenous infusion of somatostatin decreases glomerular filtration rate, renal plasma flow, urine volume (40) , and osmotic and free water clearance (34, 40) . Furthermore, somatostatin increases the fractional excretion of sodium and phosphate while decreasing plasma renin activity and urinary excretion of PGE 2 , dopamine, epinephrine, and other vasoactive factors (34) . Whereas some of the effects of systemic infusion of somatostatin are mediated by altering renal blood flow, several studies indicate that somatostatin also directly alters renal function at the cellular level. For example, somatostatin inhibits vasopressin-induced water permeability of microperfused rat papillae (22) and cAMP production in cultured rat renal collecting tubule cells (13) . We have demonstrated that somatostatin inhibits epidermal growth factor-induced renal tubular cell proliferation (36) . Somatostatin also inhibits serum-induced proliferation of rat mesangial cells (27) and ANG II-induced contraction of cultured human mesangial cells (3, 7, 8) .
The ability of somatostatin to directly modulate renal cell function implies the presence of functional somatostatin receptors (sst) in the kidney. Hatzoglou et al. (10) demonstrated that opossum kidney (OK) tubular cells express somatostatin binding sites for octreotide by radioligand binding assays. High-affinity somatostatin binding sites were also detected in rabbit kidney extracts (26) . There are at least five different somatostatin receptor subtypes (sst 1 -sst 5 ). Mitsuma et al. reported that rat kidney expresses sst 2 (16) and sst 3 (15) , but not sst 1 (17) as assessed by immunohistochemistry. However, the kidney data were provided only in tabular form in these reports, so the segmental distribution of sst receptor expression in the rat kidney could not be ascertained.
In human kidney, Yamada et al. (41) detected sst 1 and sst 2 mRNA by Northern blot analysis. The majority of renal carcinomas express sites for somatostatin, as assessed by radioligand binding assays (24) , and mRNA for sst 2 , as detected by RT-PCR (25, 39) . DiezMarques et al. (3) demonstrated specific binding of octreotide to cultured human mesangial cells corresponding to the ability of somatostatin to stimulate cGMP production and inhibit ANG II-induced mesangial cell contraction (8) . Reubi et al. (23) detected specific binding of octreotide to human renal tubules, collecting ducts, and vasa recta by in situ radioligand binding assays.
The expression pattern of somatostatin receptor subtypes in different segments of the human kidney has not previously been described. This information is crit-ical for developing strategies to utilize somatostatin subtype-selective analogs to beneficially modify renal transport functions or to treat renal diseases such as mesangial proliferative forms of glomerulonephritis. Herein, we report on somatostatin receptor subtype mRNA expression in normal human kidney for all five somatostatin receptor subtypes. We also demonstrate the segmental expression pattern of sst 1 and sst 2 by immunohistochemistry.
METHODS
Tissue procurement. Kidney tissue was provided by The Ohio State University and Children's Hospital Cooperative Human Tissue Network with approval from Children's Research Institute Human Subjects Internal Review Committee. Specimens were obtained from normal kidney adjacent to a renal tumor or from cadaveric kidneys unsuitable for renal transplanation.
RT-PCR. RT-PCR was performed with previously described (2) oligonucleotide primers for all five sst receptor subtypes and c-abl, a tyrosine kinase protooncogene constitutively expressed in glomeruli and other cell types (2, 18, 30) . Total RNA was isolated by using the TRIzol (GIBCO-BRL, Grand Island, NY) or RNAzol (CINNA/BIOTEX, Friendwood, TX) methods as described by the manufacturers. Total RNA (200 ng) was reverse transcribed with random hexamer primers followed by amplification of cDNA by PCR (GeneAmp kit; PerkinElmer Cetus, Norwalk, CT). For sst 1 -sst 3 , reaction mixtures were subjected to 33 cycles of 94°C for 1 min, 60°C for 2 min, and 72°C for 2 min For sst 4 , mixtures were subjected to 35 cycles of 94°C for 40 s, 62°C for 45 s, and 72°C for 1 min For sst 5 , PCR conditions included 1.5 mM MgCl 2 and 1.5% deionized formamide; mixtures were subjected to 30 cycles of 94°C for 30 s, 64°C for 10 s, and 72°C for 1 min. After completion of PCR cycles, reactions were subjected to 72°C for 9 min. RT-PCR products were resolved by electrophoresis at 100 V through 1% agarose in 1ϫ TAE (0.04 M Tris-acetate, 0.001 M EDTA, pH 8.0) and visualized with ethidium bromide.
Southern hybridization of sst receptor RT-PCR products. Southern analysis was used to confirm that sst 1 , sst 2 , and sst 5 RT-PCR products contained the expected sst receptor subtype-specific sequences. As previously described (2), the Southern blot probes were complementary to regions of receptor cDNA nested between the binding sites for RT-PCR primers. The RT-PCR products were transferred to a nylon membrane and hybridized with the appropriate oligonucleotide probes that were 32 P labeled with T4 polynucleotide kinase. Hybridization was performed in 50% formamide at 42°C overnight. The membranes were washed sequentially with 2ϫ standard sodium citrate (SSC; 0.3 M sodium chloride, 0.03 M sodium citrate, pH 7.0) at room temperature, 2ϫ SSC with 1% sodium dodecyl sulfate at 65°C, and then 0.1ϫ SSC at room temperature. Bound 32 P-labeled probe was detected by autoradiography. To control for nonspecific hybridization, c-abl RT-PCR products were also included on all blots.
Antisera preparation for immunohistochemistry of sst 1 and sst 2 . Antisera against sst 1 and sst 2 were generated as previously described (2) . Briefly, for generation of sst 1 antiserum, an oligonucleotide coding for the NH 2 terminal, 57 amino acids comprising the first extracellular domain of sst 1 were cloned into pET-32a(ϩ) vector (Novagen, Madison, WI) as a COOH-terminal fusion to thioredoxin by using T4 DNA ligase (TA cloning kit, Invitrogen, Carlsbad CA). Similarly, an oligonucleotide corresponding to the NH 2 terminal, 45 amino acids of sst 2 were cloned into pET-32a(ϩ). After the truncated sst 1 and sst 2 peptides were expressed by AD494 bacteria (Novagen), peptides were purified by using the Pharmacia HisTrap column system (Amersham Pharmacia Biotech, Uppsala, Sweden). Rabbits were immunized with 500 g of truncated sst 1 or sst 2 peptide in 0.5 ml 0.9% NaCl mixed with an equal volume of Freund's adjuvant. After four boosts (100 g peptide each) at 3-wk intervals, antisera were collected and stored at Ϫ70°C.
Transient transfection. Expression vectors for sst 1 , sst 2 , and sst 5 were generated as previously described (2) . OK cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured as directed. Cells were periodically tested for mycoplasma contamination by using an RT-PCR mycoplasma detection kit (ATCC). OK cells (5,000 cells per well) were plated in 8-well chamber slides (Fisher Scientific, Pittsburgh, PA) and transfected by using Effectene transfection reagent as directed by the manufacturer (Qiagen, Valencia, CA). Briefly, 0.4 g of plasmid DNA were mixed with Effectene reagent in a 1:20 ratio of DNA to Effectene. Cells were incubated with the transfection mixture overnight at 37°C. After incubation in regular growth medium at 37°C for an additional 24 h, the cells were washed once with PBS and then fixed with ice-cold 100% methanol for 10 min.
Immunofluorescence of transfected cells. For immunofluorescent staining, cells were rinsed with PBS, then blocked with "Power Block" (Biogenix, San Ramon, CA) for 30 min at room temperature. Cells were then incubated with 300 l of antisera or preimmune serum. Anti-sst 1 serum was diluted in Diluent buffer (Biomedia, Foster City, CA) 1:1,000 while anti-sst 2 serum was diluted 1:2,000. For blocking studies, antisera were preincubated for 2 h at room temperature with 50 g/ml of immunizing peptide. The mixtures were then subjected to centrifugation at 17,000 g at 4°C for 10 min, and the supernatant was used for staining. After incubation with antisera or preimmune serum at 37°C for 1 h, cells were washed three times with OptiMax wash buffer (Biogenix, San Ramon, CA). Cy3-conjugated affinity-purified anti-rabbit IgG antiserum (Jackson Laboratories, West Grove, PA) diluted 1:500 was then applied. After incubation for 1 h at 37°C in the dark, cells were washed three times with wash buffer. After being coverslipped with Vectashield mounting medium (Vector Laboratories, Burlingame, CA), cells were photographed with an Optronics Magnafire digital camera mounted on a Leica DMLB microscope.
Immunohistochemical staining of normal human kidney. For immunohistochemical analysis of sst 1 and sst 2 expression, 4-m sections of paraffin-embedded normal human kidney were placed on charged slides and deparaffinized. To block endogenous peroxidase activity, slides were incubated with PeroxiDaze 1 (Biocare Medical, Walnut Creek, CA) for 15 min at room temperature. Endogenous biotin was blocked by incubating sections in avidin-blocking solution for 15 min followed by biotin-blocking solution for 15 min (Vector Laboratories). Sections were then incubated in Power Block for 10 min. Antisera were diluted and absorbed with immunizing peptide as described above. Slides were incubated with preimmune serum or antisera at 4°C overnight. Sections were then processed with the "super sensitive multilink" staining system as described by the manufacturer (Biogenix). Briefly, after slides were washed three times, biotinylated secondary antibody was applied for 20 min at room temperature. Slides were then washed three times in wash buffer for 20 min each wash, followed by incubation in peroxidaseconjugated streptavidin for 20 min. After washing of slides http://ajprenal.physiology.org/ three times for 20 min each, 3-amino-9-ethyl-carbazole chromogen was applied for 3 to 10 min depending on development of slides. Staining was stopped by immersion in distilled water. Slides were counterstained with hematoxylin for 10 s, rinsed in water, immersed in ammonia water for 15 s, and then cemented with Crystal Mount (Biomedia), placed on a 60°C surface for 15 min, coverslipped with Permamount (Biogenix), and photographed as described above.
To determine which tubular segments express sst 1 and sst 2 , serial sections were also stained with Arachis hypogaea (AH) lectin (to define distal tubule/collecting duct cells), Phaseolus vulgaris (PHA-E) lectin (to define proximal tubules), and Tamm-Horsfall protein (THP) antiserum (to define the thick ascending limb of the loop of Henle) (19) . Lectins were obtained from Sigma (St. Louis, MO). For THP staining, a goat anti-THP (anti-human uromucoid) antiserum (Cappel/ICN, Costa Mesa, CA) was used at a 1:100 dilution. THP staining was performed as for anti-sst receptor staining except that a 1:100 dilution of biotinylated antisheep IgG (Vector) was used instead of the BioGenix multilink secondary antibody. For lectin staining, sections were prepared and blocked as for immunostaining. Sections were then incubated with biotinylated AH lectin or PHA-E lectin. Biotinylated AH and PHA-E were diluted to 0.01 mg/ml and 0.002 mg/ml, respectively. After incubation at room temperature for 1 h, slides were washed three times in wash buffer for 20 min each wash, followed by incubation in peroxidaseconjugated streptavidin for 20 min. Slides were then processed as for immunohistochemistry.
To determine the fraction of tubules coexpressing somatostatin receptor and THP, AH lectin, or PHA-E lectin, the same region of serial sections was photographed for each stain. Four separate regions were photographed, magnified, and then compared. All stained tubules in one serial section that could be clearly identified in a corresponding serial section by local landmarks were evaluated.
RESULTS
Human kidneys express mRNA for several somatostatin receptor subtypes. For RT-PCR analysis, kidney tissue from nine different donors was tested. These donors ranged in age from childhood to 69 yr of age and were evenly distributed between male and female donors (Table 1) . Unfortunately, racial information on the donors was not provided with the procurement information.
In preliminary experiments, adequacy of primers was confirmed and conditions optimized by amplifying all five sst receptor subtypes from genomic DNA. For RT-PCR, the presence of adequate amounts of RNA was confirmed by performing RT-PCR with primers specific for the protooncogene, c-abl. The sst receptor genes are intronless. Therefore, products obtained from contaminating genomic DNA are the same size as from mRNA. However, the primers for c-abl amplify across an intron/exon splice site. Reactions for c-abl did not demonstrate the presence of the genomic c-abl product (Fig. 1) indicating the absence of genomic DNA. In addition, parallel RT-PCR mixtures without RT were included in each experiment (Fig. 1) , and no contaminating DNA was detected.
RT-PCR of normal human kidney RNA with sst receptor subtype-specific primers resulted in single products of the appropriate size for sst 1 and sst 2 for all nine donors ( Fig. 1 and Table 1 ). A single donor of seven expressed sst 4 and four of nine donors expressed sst 5 . sst 3 mRNA was not detected in any of seven donors tested. These results indicate that mRNA for sst 1 and sst 2 is consistently expressed in normal human kidney. 
NAT-RCC 66 F ϩ ϩ nd nd ϩ Totals 9/9 9/9 0/7 1/7 4/9 sst 1-5 , Somatostatin receptors; M, male; F, female. NAT, normal adjacent tissue; RCC, renal cell carcinoma; ND, not defined in information provided to investigators; nd, not determined. Fig. 1 . Detection of human kidney somatostatin receptor (sst) mRNA expression by RT-PCR. Total RNA isolated from normal human kidney was subjected to RT-PCR with oligonucleotides specific for each sst receptor subtype or the protooncogene, c-abl. To control for contaminating genomic DNA, a c-abl sample was processed in an identical manner except RT was omitted (ϪRT). Products were visualized by agarose gel electrophoresis and ethidium bromide staining. Left lane: DNA molecular weight (MW) markers (100-bp ladder). This is a representative result from a single donor (donor 6). The parallel ϪRT controls for each sst receptor subtype, which were included in all experiments, are not shown.
The RT-PCR products for sst 1 , sst 2 , and sst 5 were analyzed further by Southern blot analysis to confirm that they contained the expected sst receptor subtypespecific nucleotide sequences. RT-PCR products were hybridized with a 32 P-labeled oligonucleotide complementary to sst receptor subtype-specific cDNA sequences nested between binding sites for the RT-PCR primers. To control for nonspecific hybridization, c-abl RT-PCR products were also included on all blots. RT-PCR products from two donors (donors 1 and 9) were tested for sst 1 , sst 2 , and sst 5 . The 32 P-labeled sst receptor probes hybridized specifically to the appropriate sst receptor RT-PCR products (Fig. 2) , but not to c-abl RT-PCR products (not shown). Also, no hybridization occurred when RT was omitted from the RT reaction (Fig. 2) , confirming the absence of contaminating genomic DNA. The ability of sst receptor subtypespecific probes to hybridize exclusively to the expected RT-PCR products confirms that the sst receptor subtype RT-PCR products are not amplification artifacts.
Immunohistochemical assessment of sst 1 and sst 2 expression in normal human kidney. We next tested for expression of sst 1 and sst 2 by immunohistochemical staining. To document that the anti-sst 1 and anti-sst 2 antisera bind specifically to the appropriate sst receptor subtype in kidney cells, opossum kidney (OK) cells were transfected with sst 1 , sst 2 , or sst 5 expression vectors and then assessed for binding by anti-sst 1 or anti-sst 2 antisera by using immunofluorescence (Fig.  3) . The antisera reacted only with cells transfected with the corresponding sst receptor expression vector. This result indicates that the antisera do not crossreact with other somatostatin subtypes. In addition, the specificity of the antisera was demonstrated by the ability of the immunizing peptide to block binding of the corresponding antisera to transfected cells (Fig. 3) .
We next assessed sst 1 and sst 2 expression in paraffin-embedded sections of normal human kidney (Fig.  4) . Antibody specificity was demonstrated by a lack of staining with preimmune serum (Fig. 4A) and by blocking of binding when antiserum was preincubated with the corresponding immunizing peptide (Fig. 4, D and H) .
Staining patterns from kidney tissue from four different donors were assessed (2 male and 2 female donors, age ranging from 4 to 64 yr). sst 1 was expressed exclusively in tubular cells (Fig. 4 , B and C), whereas sst 2 was expressed in both tubular and glomerular cells Fig. 2 . Southern blot analysis of sst receptor RT-PCR products. sst 1 , sst 2 , and sst 5 RT-PCR products from donor 1 were transferred to a nylon membrane and incubated with 32 P-labeled sst receptor subtype-specific synthetic oligonucleotide probes. Bound probe was visualized by autoradiography. To control for contaminating genomic DNA, samples were processed in an identical manner except RT was omitted. A 123-bp DNA MW ladder from one of the corresponding ethidium bromide-stained agarose gels is shown (left lane). This is a representative result from RT-PCR products obtained from donor 1. Similar results were obtained with RT-PCR products from donor 9 (not shown). (Fig. 4, E-G) . Expression of sst 2 in glomeruli was most consistent with a mesangial staining pattern (Fig. 4E) , but the specific glomerular cell type(s) expressing sst 2 could not be ascertained. In addition, the intensity of glomerular staining was variable among donors, ranging from light and focal staining to intense and more diffuse staining. However, glomeruli from all four donors were clearly positive for sst 2 , but not sst 1 .
In most tubules, staining for both sst 1 and sst 2 was diffuse throughout the cytoplasm. However, in some tubules, expression was predominately on the apical surface without diffuse cytoplasmic staining (not shown). Comparison of serial sections demonstrated that of all tubules expressing sst 1 or sst 2 , 40% (89/221) expressed both sst 1 and sst 2 , 54% (119/221) expressed sst 2 ϩ but not sst 1 , and only 6% (13/221) expressed sst 1 but not sst 2 (Figs. 4 and 5) . These results indicate that sst 2 is expressed more widely than sst 1 , but both sst 1 and sst 2 are expressed in renal tubules in vivo.
To define which tubular segments express sst 1 and/or sst 2 , serial sections were stained with AH lectin (to define distal tubule/collecting duct cells), PHA-E lectin (to define proximal tubules), and THP antiserum (to define the thick ascending limb of the loop of Henle) (19) . THP and AH staining overlapped considerably; of all tubules positive for either AH or THP, 43% (97 of 226 tubules) were positive for both AH and THP, 23% (52 of 226) for AH only, and 34% (77 of 226) for THP only (Figs. 5 and 6 ). There was no overlap between PHA-E ϩ and AH ϩ or THP ϩ tubules, demonstrating the specificity of these lectins and antiserum for specific tubular segments.
Tubules that could be clearly identified in corresponding serial sections were assessed for expression Fig. 5 . Staining of serial sections of normal human kidney with sst 1 and sst 2 antisera and segment-specific markers. Paraffin sections of normal human kidney were stained as described in METHODS with antiserum against sst 1 (A), sst 2 (B), Tamm-Horsfall protein (THP; C), or with biotinylated Arachis hypogaea (AH) lectin (D) or Phaseolus vulgaris (PHA-E) lectin (E). Original magnification ϫ100. The pictures are focused on one portion of the field for clarity. Single-lined arrowhead denotes a tubular segment positive for sst 1 , sst 2 , and AH, but negative for THP and PHA-E. The double-lined arrowhead denotes a tubular segment positive for sst 2 , AH, and THP, but negative for sst 1 and PHA-E. of sst 1 , sst 2 , THP, AH lectin, and PHA-E lectin (Figs. 5  and 6 ). For all tubules expressing AH, but not THP, 65 and 73% expressed sst 1 and sst 2 , respectively (Fig. 6A) . For tubules expressing both AH and THP, 51 and 84% expressed sst 1 and sst 2 , respectively (Fig. 6A) . For tubules expressing THP, but not AH, only 14% expressed sst 1 , whereas 86% expressed sst 2 (Fig. 6A) . Conversely, when all distal tubules or collecting ducts that expressed sst 1 were evaluated, 50% were AH ϩ / THP Ϫ , 39% were AH ϩ /THP ϩ , and 11% were THP ϩ / AH Ϫ (Fig. 6B) . Of all distal tubules or collecting ducts that expressed sst 2 , 30% were AH ϩ /THP Ϫ , 35% were AH ϩ /THP ϩ , and 35% were THP ϩ /AH Ϫ (Fig. 6B) . These results indicate that sst 1 and sst 2 are expressed in overlapping, but distinct, patterns in human renal cells in vivo. sst 1 is expressed predominately in AH ϩ collecting duct cells or distal tubular cells and less commonly in THP ϩ tubules. In contrast, sst 2 is more widely expressed than sst 1 and is expressed in the majority of AH ϩ and THP ϩ tubules. PHA-E ϩ tubules never stained intensely positive for either sst 1 or sst 2 (Fig. 5) . However, many proximal tubules were lightly stained with sst 2 above the background staining obtained with preimmune serum. Such sst 2 staining is especially evident in Fig. 5B .
Occasional proximal tubules were also weakly positive for sst 1 . Proximal tubular staining was blocked by preincubation with immunizing peptide. These results suggest that proximal tubules also express sst 2 and sst 1 but at a much lower level than in AH ϩ and/or THP ϩ tubules.
DISCUSSION
In this study, we discovered that somatostatin receptor subtypes 1 and 2 are expressed widely throughout the distal nephron and collecting duct in normal human kidney. The physiological source of somatostatin that might bind to these receptors is not known. We previously reported that freshly isolated human renal cortex and cultured human mesangial and tubular epithelial cells express somatostatin mRNA and that mesangial and tubular cells secrete somatostatin peptide (35, 37) . The finding that renal cells produce somatostatin and express somatostatin receptors implies that somatostatin may modulate renal function in an autocrine/ paracrine manner. In addition, circulating somatostatin may modulate renal function. Fasting plasma somatostatin concentrations are less than 0.02 nM in normal plasma samples (20) , which is below the 0.5 nM equilibrium dissociation constant (K d ) calculated for somatostatin receptors in intact human kidney (23) . However, somatostatin filtered from the circulation or secreted into the urinary space could modulate downstream tubular cell function. The finding that sst 1 and sst 2 are expressed predominately in the distal nephron and collecting duct implies that these receptors play an important role in renal function, perhaps for tubular transport or regulation of cell proliferation and differentiation. Somatostatin inhibits contraction of human mesangial cells (7, 8) , vasopressin-induced water permeability of microperfused rat papillae (22) , cAMP production in cultured rat renal collecting tubule cells (13) , and proliferation of OK proximal tubular cells (10) , human renal tubular cells (36) , and rat mesangial cells (27) .
In addition to these effects, somatostatin may have other direct effects on renal cell function and gene expression because somatostatin receptors are linked to a multitude of intracellular signaling pathways. For example, depending on which sst receptor subtype and G proteins are expressed in various cells, somatostatin can lead to inhibition of adenylate cyclase, to stimulation of tyrosine or serine/threonine phosphatase activity, activation of guanylate cyclase, or to modulation of calcium or potassium fluxes (8, 21, 41) . Somatostatin also directly inhibits insulin-like growth factor-1 (IGF-1) synthesis (29) and modulates expression of IGF-1 binding protein-1 (6) . Furthermore, somatostatin leads to inhibition of c-fos transcription and AP-1 DNA binding (31) (32) (33) . The widespread expression of somatostatin receptors in the kidney implies that somatostatin plays an important role in regulating renal cell function. Therefore, future studies aimed at understanding how somatostatin modulates kidney function, growth, and development in normal and pathological states are highly warranted.
The availability of somatostatin receptor subtypeselective analogs may allow precise manipulation of the response of renal cells to somatostatin. In recent years somatostatin analogs have been used in the treatment of a wide variety of diseases (21) . These analogs have been found to be exceptionally safe and cause relatively few side effects. We propose that somatostatin analogs may be useful to treat several renal disorders. The capacity of somatostatin analogs to inhibit proliferation of tumor cells, which correlates with sst receptor expression, is presently being utilized clinically to treat sst receptor-positive tumors (11) . Our observation that somatostatin inhibits renal tubular cell proliferation (36) and the fact that sst receptor binding sites are present on 72% of renal cell carcinomas (24) indicates that somatostatin analogs may be useful for diagnosis and treatment of this malignancy (4). Somatostatin not only inhibits proliferation of cultured rat mesangial cells (27) , it also decreases mesangial cell proliferation in vivo after subtotal nephrectomy in rats (38) . Because many forms of acute glomerulonephritis, including IgA nephropathy, membranoproliferative glomerulonephritis, and proliferative lupus nephritis, are characterized by excessive mesangial cell proliferation (1), somatostatin analogs may be useful for inhibiting excessive mesangial cell proliferation in such diseases.
Systemic administration of the somatostatin analog octreotide (100 g twice per day) for 6 mo after induction of diabetes with streptozotocin in rats decreases renal hypertrophy and urinary albumin excretion (5) . Similarly, Igarashi et al. (12) reported that octreotide treatment decreased albuminuria in diabetic rats. Furthermore, Gronbaek et al. (9) demonstrated that after three mo of untreated streptozotocin-induced diabetes, the combination of octreotide and captopril (an angiotensin converting enzyme inhibitor) was superior to captopril alone in reducing urinary albumin excretion and renal growth. Although such animal studies of diabetic nephropathy are promising, results in small clinical trials have been variable (14, 28) . However, as more knowledge is gained about the renal effects of somatostatin and somatostatin receptor expression, use of somatostatin analogs may be optimized to achieve results in humans that are similar to the results obtained in animal models of diabetic nephropathy.
We speculate that the binding of somatostatin to sst 1 compared with sst 2 will have distinct effects. The lack of staining for sst 1 in the glomerulus suggests that only sst 2 -selective analogs will influence mesangial cell function. The regulation of sst receptor expression in the kidney is not known. Thus the pattern of sst receptor subtype expression may be altered under pathological conditions. Because somatostatin influences a multitude of signaling pathways, it is clear that as more is elucidated about how somatostatin impacts on renal signaling pathways, and how renal somatostatin receptor expression is regulated, novel methods to use sst receptor subtype-selective somatostatin analogs to modulate renal cell function in pathological conditions will be developed.
